Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92


Folding of an MHC class II-restricted tumor antigen controls its antigenicity via MHC-guided processing.

Mimura Y, Mimura-Kimura Y, Doores K, Golgher D, Davis BG, Dwek RA, Rudd PM, Elliott T.

Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5983-8. Epub 2007 Mar 26.


An immunodominant MHC class II-restricted tumor antigen is conformation dependent and binds to the endoplasmic reticulum chaperone, calreticulin.

Golgher D, Korangy F, Gao B, Gorski K, Jaffee E, Edidin M, Pardoll DM, Elliott T.

J Immunol. 2001 Jul 1;167(1):147-55.


Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.

Matsuzaki J, Tsuji T, Luescher I, Old LJ, Shrikant P, Gnjatic S, Odunsi K.

Cancer Immunol Res. 2014 Apr;2(4):341-50. doi: 10.1158/2326-6066.CIR-13-0138. Epub 2013 Dec 17.


Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.

Neeley YC, McDonagh KT, Overwijk WW, Restifo NP, Sanda MG.

Prostate. 2002 Nov 1;53(3):183-91.


Immune selection in murine tumors. Ph.d thesis.

Svane IM, Engel AM.

APMIS Suppl. 2003;(106):1-46.


Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.

Topalian SL, Rivoltini L, Mancini M, Ng J, Hartzman RJ, Rosenberg SA.

Int J Cancer. 1994 Jul 1;58(1):69-79.


Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.

Kissick HT, Sanda MG, Dunn LK, Arredouani MS.

PLoS One. 2014 Apr 1;9(4):e93231. doi: 10.1371/journal.pone.0093231. eCollection 2014.


Correlation between expression of major histocompatibility complex class I and that of antigen presenting machineries in carcinoma cell lines of the pancreas, biliary tract and colon.

Imanishi T, Kamigaki T, Nakamura T, Hayashi S, Yasuda T, Kawasaki K, Takase S, Ajiki T, Kuroda Y.

Kobe J Med Sci. 2006;52(3-4):85-95.


Presentation of arthritogenic peptide to antigen-specific T cells by fibroblast-like synoviocytes.

Tran CN, Davis MJ, Tesmer LA, Endres JL, Motyl CD, Smuda C, Somers EC, Chung KC, Urquhart AG, Lundy SK, Kovats S, Fox DA.

Arthritis Rheum. 2007 May;56(5):1497-506.


Molecular cloning and characterization of MHC class I- and II-restricted tumor antigens recognized by T cells.

Wang RF.

Curr Protoc Immunol. 2009 Feb;Chapter 20:Unit 20.10. doi: 10.1002/0471142735.im2010s84.


MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer.

Poli C, Raffin C, Dojcinovic D, Luescher I, Ayyoub M, Valmori D.

Haematologica. 2013 Feb;98(2):316-22. doi: 10.3324/haematol.2012.071712. Epub 2012 Aug 8.


Asparagine endopeptidase is not essential for class II MHC antigen presentation but is required for processing of cathepsin L in mice.

Maehr R, Hang HC, Mintern JD, Kim YM, Cuvillier A, Nishimura M, Yamada K, Shirahama-Noda K, Hara-Nishimura I, Ploegh HL.

J Immunol. 2005 Jun 1;174(11):7066-74.


Recognition of a shared human prostate cancer-associated antigen by nonclassical MHC-restricted CD8+ T cells.

Housseau F, Bright RK, Simonis T, Nishimura MI, Topalian SL.

J Immunol. 1999 Dec 1;163(11):6330-7.


LAMP-2-deficient human B cells exhibit altered MHC class II presentation of exogenous antigens.

Crotzer VL, Glosson N, Zhou D, Nishino I, Blum JS.

Immunology. 2010 Nov;131(3):318-30. doi: 10.1111/j.1365-2567.2010.03309.x.

Supplemental Content

Support Center